Review finds too little evidence that programs reduce alcohol use in people with cancer
Eight randomized trials showed mixed results, and differences between studies prevented a formal combined analysis.
Moderate evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers reviewed randomized trials of programs intended to reduce alcohol use among people living with cancer. The review included eight trials with 1,437 participants, but the programs and measurement methods varied widely, so the researchers could not combine the results in a formal meta-analysis.
Some studies reported results that favored the programs, especially at two to three months. However, all of the trials had unclear or high risk of bias, and the review concluded that there is not enough reliable evidence to determine whether health-behaviour programs reduce alcohol consumption in this population.
What the review covered
The researchers systematically searched five databases for randomized controlled trials published from January 2000 through April 2025. They found eight trials involving 1,437 people living with cancer. Two trials specifically targeted alcohol reduction, while six included alcohol use within broader programs addressing multiple health behaviours. Alcohol consumption was measured by self-report, using different measures across studies. Because the studies were substantially different and few in number, the researchers used a structured narrative summary and counted the direction of findings instead of conducting a meta-analysis.
What the review concluded
At two to three months, all five studies that reported results favored the intervention, but the result did not meet the review's stated statistical threshold (p = 0.063). At five to six months, 57% of seven studies favored the intervention, and at 12 months, 67% of three studies did so. These figures describe the direction of the study results; they do not confirm that the programs caused a reduction in alcohol use or show the size of any change. The review therefore found insufficient evidence that health-behaviour interventions effectively reduce alcohol consumption among people living with cancer.
Who this is relevant to
These findings are most relevant to people living with cancer who are similar to participants in the eight included trials. They do not show that any particular program works for all people with cancer, and the review does not identify a clearly effective approach.
What this could mean
Alcohol use can be one of the health behaviours considered in cancer survivorship research, so understanding whether behavioural programs affect it is relevant to patients, clinicians, and researchers. This review indicates that the available research does not yet provide a dependable answer about effectiveness. It also points to the need for better-designed studies that examine alcohol-focused programs and the reasons alcohol use may differ among people living with cancer. These implications concern research evidence, not individual medical care decisions.
Limitations & evidence assessment
Only eight trials, involving 1,437 people, were eligible, and the studies differed substantially in their participants, programs, and ways of measuring alcohol use. Six of the eight programs addressed alcohol as part of broader health-behaviour support rather than targeting alcohol specifically. Alcohol intake was self-reported using different measures, and every study was judged to have unclear or high risk of bias. Follow-up results were available at different time points, and the evidence was summarized by counting whether study results pointed in the intervention's direction rather than combining effect sizes; this method cannot establish whether a real effect existed or how large it was. The abstract provides limited information about the individual trial populations and intervention details.
Why this evidence level: This was a systematic review of randomized controlled trials, which can provide relatively strong evidence. However, only eight small and varied trials were available, all had unclear or high risk of bias, and the researchers could not perform a meta-analysis, so confidence in the overall conclusion is limited.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Journal of Cancer Survivorship · 2026 · DOI: 10.1007/s11764-026-02065-7
This review analyzed human studies comparing two treatments given before surgery for locally advanced esophageal or esophagogastric junction adenocarcinoma: FLOT chemotherapy and CROSS chemoradiotherapy. The pooled estimate favored FLOT for overall survival, but the groups had similar three-year survival, tumor response, surgical margins, and several major perioperative outcomes.
A systematic review examined whether Passiflora edulis, commonly known as passion fruit, is linked with lower blood pressure. It included six preclinical studies and two human trials; the animal and laboratory findings were generally more extensive than the human evidence. The authors reported possible blood-pressure reductions but emphasized that the human studies were small, varied in the extracts used, and short in duration.
Researchers studied 96 people with high-risk, locally advanced rectal cancer in a single-center phase II clinical trial. The treatment combined chemotherapy, short-course radiation, and a targeted drug selected for each study cohort. Overall, 40% had a complete response, but the study did not establish how this approach compares with other treatments.
